Press Release 24 July 2008 BioGaia completes its Latin American market coverage and signs agreement for Switzerland BioGaia extends its agreement with Ferring Pharmaceuticals to cover basically the whole of Latin America, giving Ferring exclusive rights to sell BioGaia´s Probiotic chewable tablets and drops in 10 additional countries: Colombia, Costa Rica, Nicaragua, Panama, Dominican Republic, Guatemala, Honduras, Cuba, El Salvador, and Trinidad-Tobago. The products will be sold under the BioGaia trademark. Ferring is a Swiss-based research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology. In recent years Ferring has expanded beyond its traditional European base and has offices in over 40 countries. To learn more about Ferring or its products please visit www.ferring.com. "Motivated by the success of our collaboration in several different countries, both with medical professionals and patients, we are delighted to make BioGaia products available in additional countries in Latin America" says Edvard Philipson, Regional VP Ferring for Latin America. BioGaia has also signed a distribution agreement with the Swiss based company AllergyCare AG which gives AllergyCare exclusive rights to sell BioGaia's Probiotic drops and tablets in Switzerland and Liechtenstein. The products will be sold under the BioGaia trademark. AllergyCare is a pharmaceutical company operating in Switzerland and Liechtenstein, focusing in marketing and sale of products with clinically documented health benefits in the areas of allergy, paediatrics and dermatology. "Biogaia's products perfectly match and complement our company's philosophy and strategy, which is the proposal of new approaches and new solutions to the medical community, with the support of opinion leaders in the country", says Bruna Ofner, General Manager of AllergyCare AG. “We are pleased to have covered some white spots in our distribution network through these agreements with two very strong and dedicated distributors” says Peter Rothschild, President, BioGaia AB. Latest press releases from BioGaia: 2008-06-24 BioGaia extends partnership with Verman 2008-04-29 BioGaia in strategic alliance with BERICAP 2008-04-23 Annual General Meeting of BioGaia For additional information contact: Peter Rothschild, Managing Director, telephone: +46 8 - 555 293 00, Jan Annwall, Deputy Managing Director telephone: +46 8 - 555 293 00 -------------------------------------------------------------------------------- --------------------------------------------------------------- BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm. www.biogaia.com
2008-07-24 BioGaia completes its Latin American market coverage and signs agreement for Switzerland
| Source: BioGaia AB